Roche killed two Huntington's disease programs on the same day, including the long-running tominersen partnership with Ionis. The drug lowered the toxic protein beautifully; it just didn't help patients. For a disease that's now racked up a half-decade of high-profile failures, the pipeline has never been wider or more uncertain.
Imagine spending over a decade building a house, watching the foundation crack, rebuilding anyway, and then walking away from both the original and the renovation on the same day.
That's essentially what Roche just did in Huntington's disease.
On July 9, 2026, the Swiss pharma giant terminated two Huntington's programs simultaneously: tominersen, an antisense oligonucleotide (ASO) developed with Ionis Pharmaceuticals, and RG6496, a next-generation follow-up designed to be smarter than its predecessor. No open-label extensions. No compassionate use. No further development. The lights are off.
For the roughly 41,000 Americans living with Huntington's, a brutal inherited disease that slowly destroys movement and cognition, this is another gut punch in a decade full of them.
The Drug That Hit the Target but Missed the Point
Tominersen was supposed to be a breakthrough. The idea was elegant: inject an ASO (a short strand of synthetic genetic material) into spinal fluid to lower levels of huntingtin protein, the toxic molecule that poisons brain cells in Huntington's patients. Think of it like turning down the volume on a speaker blasting static.
Early results looked promising. In a Phase 1/2a trial starting in 2015, tominersen successfully reduced mutant huntingtin in cerebrospinal fluid. Roche licensed it from Ionis in 2017 and charged straight into a massive Phase 3 trial called GENERATION HD1, enrolling roughly 800 patients across 18 countries.
Then things fell apart. In March 2021, an independent safety board told Roche to stop dosing. Patients getting the drug every eight weeks were actually doing worse than those on placebo. The benefit-risk profile was, in the committee's polite phrasing, "unfavorable."
But Roche didn't give up entirely. Post-hoc analyses (the scientific equivalent of reviewing game tape after a loss) hinted that younger patients with less disease might still benefit. So Roche redesigned the play: a new Phase 2 trial called GENERATION HD2, focused on prodromal and early-stage patients with lower, less frequent doses.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The result? Same story, different chapter. The trial met its safety targets. Biomarkers moved in the right direction; both mutant huntingtin and neurofilament light chain (a marker of nerve damage) went down. But the clinical endpoints that actually matter, the composite scores measuring movement and daily function at 16 months, showed no meaningful improvement over placebo.
Roche's conclusion: there is "no path forward" for tominersen.
The Backup Plan That Never Got Off the Ground
RG6496 was supposed to be the smarter sibling. Unlike tominersen, which lowers all huntingtin (both the toxic mutant version and the normal one your brain actually needs), RG6496 was allele-selective. It targeted only the mutant copy by zeroing in on a specific genetic marker called a SNP.
The first-in-human trial, called POINT-HD, had enrolled just three patients when Roche pulled the plug. The reason wasn't anything that happened in those patients; their single doses appeared safe. The problem came from animal studies running in parallel.
Long-term, repeated dosing in animals revealed findings that made chronic treatment impossible. And chronic treatment is the only kind that matters for a disease like Huntington's, which grinds on relentlessly over years. A drug you can only give once is like an umbrella you can only open indoors.
Roche stressed that both terminations were "independent, data-driven events" that happened to land on the same painful day.
The Graveyard Keeps Getting Bigger
Roche isn't alone in striking out. The last five years have been a wrecking ball for Huntington's drug development:
Wave Life Sciences abandoned two allele-selective ASOs in March 2021 after they failed to adequately lower mutant huntingtin. Novartis killed its oral candidate branaplam in December 2022 when patients developed nerve damage. Triplet Therapeutics, a startup focused on repeat-expansion diseases, shut down entirely in 2022 after investors lost faith. Even uniQure's gene therapy AMT-130 hit turbulence when three of 14 patients in the high-dose group experienced serious side effects.
The common thread? Lowering huntingtin protein in a test tube, or even in spinal fluid, simply hasn't translated into helping patients feel or function better. It's like proving you can drain water from a flooded basement without actually stopping the leak.
What Roche Has Left (and What Everyone Else Is Trying)
Roche isn't completely out of the Huntington's game. It still has RG6662, a gene therapy inherited from the Spark Therapeutics acquisition, in Phase 1/2 testing. And its 2023 collaboration with Ionis on a new, undisclosed HD target remains active in preclinical development.
Meanwhile, the broader pipeline has diversified significantly. PTC Therapeutics is advancing an oral pill called PTC518 that lowers huntingtin through a splicing mechanism, with Phase 2 data that could move toward Phase 3. Skyhawk Therapeutics has SKY-0515, another oral splicing modulator that reportedly achieved around 62% reduction in mutant huntingtin in early data; Australia's drug regulator has already flagged it for a provisional approval pathway.
On the injectable front, Alnylam is testing an siRNA therapy (ALN-HTT02) in Phase 1, while Sarepta won approval from New Zealand's Medsafe to start a first-in-human trial of its own siRNA candidate. Further out, companies like Harness and LoQus23 are exploring an entirely different strategy: blocking the CAG repeat expansion itself, essentially trying to stop the genetic mutation from getting worse over time.
Patient advocacy groups describe the current pipeline as the first genuinely credible wave of disease-modifying strategies. But credible and successful are two very different words.
What This Means for Ionis
For Ionis, losing two partnered Huntington's programs stings but doesn't fundamentally change the company's trajectory. In a statement, Ionis said it "shares Roche's deep disappointment" and quickly redirected attention to zilganersen, its wholly owned drug for Alexander disease. It also pointed to olezarsen for severe hypertriglyceridemia, another planned 2026 launch.
Ionis still has three FDA-approved neurologic drugs and more than 10 investigational therapies across Alzheimer's, Parkinson's, ALS, and other conditions. Analysts are likely to treat this as a hit to long-term option value in Huntington's rather than a thesis-breaking event.
The bigger question isn't about Ionis's stock price. It's about whether the entire huntingtin-lowering hypothesis needs rethinking, or just better execution. Tominersen proved you can lower the protein. It just couldn't prove that lowering the protein is enough.
For Huntington's families, the wait continues. The pipeline is more diverse than ever. But diversity of approaches, after this many failures, feels less like abundance and more like the field still searching for the right answer.
5 min read
The Only Drug That Can Save These Babies Is Being Pulled Off Shelves
Pfizer just recalled lots of the only drug recommended to treat syphilis in pregnant women, compounding a shortage that's already lasted years. With congenital syphilis cases at historic highs, public health officials are calling it a preventable tragedy in slow motion.
